Moderna doubles on cancer-vaccine progress — Korean retail rotates back into ADR book
Moderna (MRNA) doubling on cancer-vaccine progress reverses its post-COVID short-favourite status and re-anchors the mRNA-oncology platform thesis. Korean retail via Kiwoom, Mirae Asset and Toss Securities was heavily short-side positioned on the trade — the unwind is now the flow story. Read-through positive for BioNTech (BNTX), Korean domestic mRNA names SK Bioscience and ST Pharm, plus the broader biotech capex conversation.
Read at 조선일보 (경제) ↗